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Objective: Unfiltered coffee raises serum LDL cholesterol in humans, owing to the presence of the diterpenes
cafestol and kahweol. Norwegians with a chronic high intake of unfiltered coffee also had elevated serum levels
of lipoprotein(a), an LDL-like particle which is insensitive toward dietary interventions. We now experimentally
studied the influence of coffee diterpenes on lipoprotein(a) levels.
Design: Four randomised controlled trials.
Subjects: Healthy, normolipidemic volunteers.
Interventions: Coffee, coffee oil, and pure diterpenes for 4–24 weeks.
Main outcome measures: The circulating level of lipoprotein(a).
Results: In 22 subjects drinking five to six strong cups of cafetiere coffee per day, the median fall in
lipoprotein(a) was 1.5 mg/dL after two months (P 0.03), and 0.5 mg/dL after half a year (P> 0.05), relative to
24 filter coffee drinkers. Coffee oil doses equivalent to 10–20 cups of unfiltered coffee reduced lipoprotein(a)
levels by up to 5.5 mg/dL (P< 0.05) in two separate trials (n 12–16 per group). A purified mixture of cafestol
and kahweol, as well as cafestol alone, were also effective in reducing Lp(a) levels (n 10). Averaged over the
four trials, each 10 mg/d of cafestol (plus kahweol)—the amount present in two to three cups of cafetiere
coffee—decreased Lp(a) levels by 0.5 mg/dL or 4% from baseline values after four weeks (n 63).
Conclusions: Coffee diterpenes are among the few dietary exceptions shown to influence serum lipoprotein(a)
levels. However, the Lp(a)-reducing potency of coffee diterpenes may subside in the long run, and their adverse
side effects preclude their use as lipoprotein(a)-reducing agents.
Sponsorship: Supported by the Netherlands Heart Foundation through grant No. 900-562-091 of the Netherlands
Organization of Scientific Research (NWO), plus supplemental funding by the Institute for Scientific Information
on Coffee.
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Introduction
Lipoprotein(a) [Lp(a)] is a liver-derived lipoprotein particle
that is only distinguished from low-density-lipoprotein
(LDL) by the covalent attachment of a large glycoprotein,
apolipoprotein(a) (Dahle´n, 1994). An extensive body of
laboratory evidence indicates a critical role of Lp(a) in the
development of atherothrombotic diseases (Marcovina &
Morrisett, 1995), which is confirmed by most (Rosengren et
al, 1990; Sigurdsson et al, 1992; Wald et al, 1994; Cremer
et al, 1994; Bostom et al, 1994; Schaefer et al, 1994; Terres
et al, 1995; Bostom et al, 1996), though not all (Jauhiainen
et al, 1991; Ridker et al, 1993; Alfthan et al, 1994; Ridker
et al, 1995), prospective cohort studies. The circulating
level of Lp(a) is largely under genetic control (Boerwinkle
et al, 1992), and is unaffected by many interventions
known to affect LDL metabolism, including most dietary
interventions (Berglund, 1995).
The diterpenes cafestol and kahweol are lipids that are
unique to coffee beans (Viani, 1986). They are responsible
for the cholesterol-raising effect of Scandinavian boiled
coffee (Weusten-van der Wouw et al, 1994; Heckers et al,
1994). Cafestol and kahweol strongly affect lipid metabo-
lism with short-term intake (Bak & Grobbee, 1989; Aro et
al, 1987; van Dusseldorp et al, 1991; Ahola et al, 1991;
Aro et al, 1990; Urgert et al, 1996a) as well as in life-long
consumers of unfiltered coffee (Bønaa et al, 1988; Stens-
vold et al, 1989; Weusten-van der Wouw et al, 1994;
Pietinen et al, 1990; Lindahl et al, 1991). We recently
found that consumption of boiled coffee was also asso-
ciated with Lp(a) levels; the median Lp(a) level in Norwe-
gians who were life-long consumers of boiled coffee was
65% higher than in matched filter coffee drinkers (Urgert et
al, 1996b).
We now report the effects of preparations rich in
cafestol and kahweol on Lp(a) levels in healthy, normolipi-
demic volunteers in four independent experiments. The
effects on serum lipids and liver enzymes have been
reported elsewhere (Weusten-van der Wouw et al, 1994;
Urgert et al, 1996a; Urgert et al, 1997a).
Methods
Subjects
Participants were recruited through advertisements in
newspapers and university buildings. Most subjects were
young, nonobese, and normolipidemic (Table 1), and all
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were apparently healthy as indicated by a medical ques-
tionnaire and by the absence of anaemia, glucosuria, or
proteinuria. None took medications known to affect serum
lipid levels. The experimental protocols, which were
approved by the local human ethics committee, were care-
fully explained to the volunteers and their written informed
consent was obtained.
Subjects were asked to maintain their usual diet and life-
style, and not to consume more than twenty drinks contain-
ing alcohol per week. They were allowed to use paper-
filtered or instant coffee, as these are free from diterpenes
(Urgert et al, 1995). All subjects kept daily records of
illness, medication use, and deviations from the protocol.
Treatments and designs
Between 1991 and 1995, we carried out four randomised
trials. We gave filtered versus unfiltered coffee in trial A,
placebo versus coffee oil in trials B and C, and cafestol
versus a mixture of cafestol and kahweol in trial D. The
experimental designs are given in Figure 1.
Trial A—unfiltered vs filtered coffee. This was a random-
ised, parallel controlled study. After a run-in period of four
weeks on filtered coffee, subjects consumed 0.9 l of either
filtered or cafetiere (also called ‘French press’) coffee per
day for 24 weeks. All ground coffee was Roodmerk
(Douwe Egberts, Utrecht, The Netherlands), a blend of
Arabica and Robusta beans widely used in the Netherlands
(van Dusseldorp et al, 1991). Cafetiere coffee provided
38 mg of cafestol and 33 mg of kahweol and filtered coffee
less than 1 mg of either diterpene per day. Six subjects
withdrew during the treatment period for personal reasons,
and one was withdrawn as he started taking drugs of
potential hepatoxicity daily during the trial.
Trials B and C—coffee oil vs placebo oil. These were
double-blind, randomised parallel controlled studies. All
participants first received for 1–2 weeks placebo oil which
was a 3:2 (w/w) mixture of sunflower oil and palm oil.
After randomization, subjects continued on either placebo
oil or coffee oil for four weeks. Daily amounts of diter-
penes provided by the coffee oil were 85 mg of cafestol and
103 mg of kahweol in trial B, and 57 mg of cafestol and
69 mg of kahweol in trial C. In trial C, a third group of
subjects received coffee oil that was stripped of cafestol
and kahweol.
There were no dropouts in trial B. Two subjects with-
drew from trial C for reasons unrelated to treatment.
Trial D—cafestol plus kahweol vs cafestol alone. This
was a double-blind, randomised cross-over study. Partici-
pants received placebo oil during the first two weeks.
During the next four weeks, half of the subjects received
64 mg of cafestol and 1 mg of kahweol dissolved in
placebo oil. The other five subjects received 60 mg of
cafestol and 54 mg of kahweol per day, again dissolved
in placebo oil. After a wash-out period of seven weeks,
subjects again received placebo oil for two weeks, and
supplements were switched during the next four weeks;
analysed dosages of cafestol and kahweol were now 61 and
0 mg for pure cafestol, and 60 and 48 mg for the mixture,
respectively. Purities of the diterpene preparations were
higher than 92%; impurities consisted of free cafestol and
kahweol, cafestol and kahweol dipalmitate, and palmitic
acid.
Three subjects were switched to placebo after two weeks
of treatment, because they exceeded our predefined safety
limits for rises in alanine amino transferase. For these
subjects, values obtained after two weeks replaced their
final values.
Serum analyses
Venous blood samples were taken after an overnight fast.
Serum samples were obtained by centrifugation, stored at
780C, and analysed blindly within 12 months after
completion of the studies.
Table 1 Characteristics of the participants of the four randomised, controlled trials. Values were
obtained at the end of the run-in periods, when subjects had received five cups of filtered coffee free
from diterpenes for four weeks (trial A), or 2–3 g of placebo oil for one or two weeks (trials B–D)a
Trial A Trial B Trial C Trial D
Number of men/women 23/23 15/17 21/15 10/0
Women using contraceptive steroid (n) 11 10 12 —
Smokers (n) 16 5 3 2
Age (y) 29 10 22 2 22 2 24 4
Body Mass Index (kg/m2)b 22 3 22 2 22 2 21 2
Serum cholesterol (mmol/L) 4.9 0.7 4.5 0.5 4.5 0.7 4.8 0.9
Serum LDL cholesterol (mmol/L) 3.0 0.8 2.5 0.5 2.7 0.6 3.0 0.7
Serum HDL cholesterol (mmol/L) 1.5 0.3 1.5 0.3 1.4 0.3 1.5 0.4
Serum triglycerides (mmol/L) 1.1 0.4 1.0 0.3 0.9 0.3 0.8 0.2
aValues are numbers, or means  s.d.
bBody weights were measured without shoes or heavy clothing.
Figure 1 Experimental designs of four randomised studies with healthy
normolipidemic volunteers. Arrows indicate times of blood sampling.
Empty cells indicate wash-out and follow-up periods, during which no
treatment was given.
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For trials B anc C, Lp(a) was measured with a solid
phase two-site immunoradiometric assay (RIA) from Phar-
macia Diagnostics AB (Uppsala, Sweden). The intra- and
inter-assay coefficients of variation as given by the manu-
facturer were 3.3 and 10.6%, respectively. The range of
measurable serum Lp(a) concentrations was 1.7–84.0 mg/
dL. Sera with concentrations higher than 84.0 mg/dL were
diluted and remeasured. Six out of 78 subjects had Lp(a)
levels less than 1.7 mg/dL. These were designated unde-
tectable. The results were recalculated from arbitrary units
to milligrams per decilitre on the basis of the results
obtained with the kit calibrators, and the value of a serum
standard from Immuno A.G. (Vienna, Austria).
For trials A and D, Lp(a) was measured with an enzyme-
linked immuno-sorbent assay (TintElize Lo(a), Campro
Scientific, Veenendaal, the Netherlands). The lower limit
of detection of Lp(a) was 1 mg/dL. None of the subjects
had levels below the detection limit. The intra- and inter-
assay coefficients of variation for a control pool of 44 mg/
dL as measured in our laboratory were 5.0% and 3.5%,
respectively.
For all trials, sera were analysed in duplicate in two
separate runs, but with one full series of samples obtained
from one subject analysed within the same run. Lipids,
lipoproteins, and liver enzymes in serum (Weusten-van der
Wouw et al, 1994), and cafestol and kahweol in coffee
preparations (Urgert et al, 1995), were assayed as
described.
Statistical analyses
We calculated the Lp(a) response of each subject by
subtracting values obtained after the run-in period (baseline
values) from those obtained during the treatment period
(treatment values). As some of the responses showed non-
Gaussian distributions, we used Mann Whitney U tests to
compare control and treatment groups. In trial D, responses
were analysed using Wilcoxon Rank Sum tests.
Results
Diaries kept by the subjects showed that more than 98% of
the diterpene preparations had been taken in each of the
trials.
Trial A—unfiltered vs filtered coffee. Daily consumption
of five cups of cafetiere coffee produced a fall in Lp(a)
levels, which reached a maximum of 1.5 mg/dL after eight
weeks (P 0.03), relative to filtered coffee (Figure 2). The
reduction stabilised around 0.5 mg/dL (P> 0.05) between
12 and 24 weeks of consumption.
Trials B and C—coffee oil vs placebo oil. In trial B,
intake of 3 g of coffee oil per day for four weeks caused a
median fall in Lp(a) levels of 5.3 mg/dL, relative to
concurrent controls receiving placebo oil (P< 0.001). In
trial C, intake of 2 g/d of coffee oil reduced Lp(a) levels by
3.1 mg/dL (P 0.02). Coffee oil that was stripped of
cafestol and kahweol did not affect Lp(a) levels.
Trial D—cafestol plus kahweol vs cafestol alone. The
mixture of cafestol and kahweol as well as cafestol alone
both reduced Lp(a) levels by 3–4 mg/dL relative to base-
line levels (Table 2). Relative to cafestol alone, the mixture
produced a median fall in Lp(a) levels of 0.8 mg/dL, and a
mean fall of 0.5 (s.e.m. 0.6) mg/dL (both P> 0.05).
Changes in Lp(a) were not associated with changes in
other serum lipids and lipoproteins, or in liver enzymes
(P> 0.05). In all four experiments, Lp(a) levels returned to
baseline values after cessation of treatment.
We combined the individual data of the four trials and
classified all subjects according to initial Lp(a) value
Figure 2 Trial A: Median changes in serum levels of lipoprotein(a)
[(Lp(a)] in subjects consuming five cups of cafetiere (!, n 22) or filtered
coffee (m, n 24) per day for 24 weeks, and the difference between the
changes (d) No treatment was given in the follow-up period.
Table 2 Effect of daily intake of preparations rich in coffee diterpenes for four weeks on serum lipoprotein(a) [Lp(a)] in four randomised, controlled
trials. Subjects received filtered coffee (trial A) or placebo oil (trials B-D) in the run-in periodsa,b
No. of subjects
Diterpene content of
preparation Baseline level of Lp(a)
Lp(a) response after 4 weeks
of treatment
Cafestol Kahweol Median Kahweol Median Mean s.d.
mg/day mg/day mg/dL mg/dL mg/dL mg/dL
Trial A Filtered coffee 24 1 1 9.2 20.8 22.3 0.3 0.2 0.8
Cafetiere coffee 22 38 33 9.8 15.2 19.9 70.9 72.0 0.9*
Trial B Placebo oil 16 0 0 17.2 25.9 23.8 0.5 1.1 0.9
Coffee oil 16 85 103 14.9 29.1 32.7 74.8** 75.5 1.4**
Trial C Placebo oil 15 0 0 17.7 24.4 23.4 0.8 71.0 1.6
Coffee oil 15 57 69 9.2 16.6 16.6 72.3* 74.5 1.3
Coffee oil stripped of
cafestol and kahweol
16 0 0 12.8 22.1 25.5 70.3 71.1 1.3
Trial D Cafestol 10 63 1 11.5 13.9 7.5 73.5c 73.5 0.8c
Cafestol plus kahweol 10 60 51 11.5 13.9 7.5 73.1c 73.9 1.0c
aChanges were compared with Wilcoxon Rank Sum test and Mann Whitney U-tests for medians, and the t-tests for means.
bResponse different from control group; *P< 0.05; **P< 0.01.
cResponse different from zero: P< 0.01.
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(Figure 3). On an absolute basis, individuals with high
initial Lp(a) values appeared to benefit more from diterpene
intake; the median fall of Lp(a) was 70.3 mg/dL in the
lowest, 73.3 mg/dL in the middle, and 76.5 mg/dL in the
upper tertile in subjects who received diterpenes, each
relative to the median change in the corresponding tertile
of controls.
Discussion
Preparations rich in the coffee diterpenes cafestol and
kahweol reduced serum Lp(a) levels in four independent
experiments. Females taking oral contraceptives were ran-
domised over control and treatment groups, and one of the
subjects took medications on a regular basis. Bias due to
hormone intake or drug therapy (Berglund, 1995) is thus
unlikely. Furthermore, changes in dietary intakes, body
mass, and alcohol use were minimal and similar for the
control and treatment groups within each study (Weusten-
van der Wouw et al, 1994; Urgert et al, 1996a; Urgert et al,
1997a). Therefore, it is unlikely that the reductions in Lp(a)
levels were due to anything else than treatment with coffee
diterpenes.
Despite its structural similarity to LDL, the circulating
level of Lp(a) is remarkably insensitive to dietary interven-
tion; by now, only dietary trans fatty acids have consis-
tently been proven to be effective, as they modestly raise
Lp(a) levels (Mensink et al, 1992; Nestel et al, 1992;
Almendingen et al, 1995). Fish oils (Beil et al, 1991;
Haglund et al, 1994) as well as high doses of ascorbic
acid (Rath, 1992) were found to reduce Lp(a) levels, but
other attempts could not verify this (Malle et al, 1991; Berg
Schmidt et al, 1991; Salvi et al, 1993; Eritsland et al, 1995;
Bostom et al, 1995). Coffee diterpenes are thus among the
few dietary components that modulate the circulating level
of Lp(a).
Intake of cafestol alone was effective in reducing Lp(a)
levels, and the addition of kahweol had little extra effect
(trial D). Cafestol may thus be the sole Lp(a)-reducing
principle in coffee oil. However, this trial was too small to
fully exclude an additional effect of kahweol.
Health benefits. Individuals with high initial values of
Lp(a) showed a larger drop in Lp(a) levels than those with
low initial values (Figure 3). The median fall across the
four experiments depended on the daily amount of cafestol
ingested. Under the assumption that the relationship is
Figure 4 Relation of the observed median change in lipoprotein(a)
[Lp(a)] after four weeks of treatment with the average cafestol intake
per day (Table 2) across the four trials. The responses are given relative to
the median changes in the respective control groups.
Figure 3 Individual baseline values (upper panels) and changes in serum lipoprotein(a) [Lp(a)] after four weeks (lower panels) in subjects who received
placebo (control subjects, n 71) or preparations rich in cafestol and kahweol (treatment subjects, n 63) in four randomised, controlled trials.
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linear, each 10 mg—the amount present in two to three
cups of cafetiere coffee—reduced Lp(a) levels by 0.5 mg/
dL or 4% from baseline level after four weeks (Figure 4).
We would expect the same effect with Turkish and Scan-
dinavian boiled coffee, as these types contain similar
diterpene levels per cup as cafetiere coffee. For espresso
coffee, about six cups per day are needed for a similar
effect (Urgert et al, 1995).
Could a lowering of Lp(a) levels with consumption of
coffee diterpenes confer any health benefit? In a meta-
analysis of eleven trials with preparations rich in cafestol
and kahweol, we found that each 10 mg of cafestol
ingested per day raises serum total cholesterol by
0.15 mmol/L, which was mostly due to an increase in
LDL cholesterol (Urgert & Katan, 1997b). The hypercho-
lesterolemic potency of coffee diterpenes thus overrules
their potential beneficial impact on Lp(a) levels. This is
evidenced by a higher rate of coronary heart disease in
coffee drinkers in Norway (Tverdal et al, 1990), where
boiled coffee is more common. Coffee diterpenes as such
are thus unsuitable as a means of treatment for elevated
Lp(a) levels, and a switch from filtered to unfiltered coffee
is not warranted.
Short-term vs chronic intake. The present findings contra-
dict our previous observation in a cross-sectional study that
Norwegian boiled-coffee drinkers had higher Lp(a) levels
than filter coffee drinkers (Urgert et al, 1996b).
The reason for this discrepancy is unknown. In our
cross-sectional study and in each of the trials described
here, serum samples of subjects who had ingested diter-
penes and those of control subjects had been stored at
780C for a similar period with a maximum of one year.
Therefore, even if sample storing has affected Lp(a) levels,
it is unlikely that it has affected the cross-sectional study
and the experiments in opposite directions.
A second explanation could be the presence of some
unknown confounding factor in our cross-sectional study,
although the insensitivity of Lp(a) levels to environmental
factors (Berglund, 1995) argues against this possibility.
Still, confounding by genetic differences cannot be fully
excluded: all subjects were living in Southern Norway, but
more people consuming boiled coffee may have descended
from ancestors originating from northern Norway, where
boiled coffee is more common (Stensvold et al, 1989).
In trial A, Lp(a) levels were depressed by up to 15% in
the first two months of intake of cafetiere coffee, but the
effect was strongly attenuated with prolonged use (Figure
2). This indicates that the reducing effect of cafestol and
kahweol may subside with prolonged intake. For other
agents known to influence the serum level of Lp(a), this
could have important implications. For instance, the evi-
dence for the Lp(a)-elevating of dietary trans fatty acids is
derived from short-term experiments only (Mensink et al,
1992; Nestel et al, 1992; Almendingen et al, 1995). The
present findings emphasize the need for intervention trials
of longer duration in studying effects of diet or drugs on
Lp(a) levels.
Mechanism. Short-term intake of coffee diterpenes raises
serum levels of alanine amino transferase (Weusten-van der
Wouw et al, 1994; Urgert et al, 1995; Van Rooij et al,
1995; Urgert et al, 1996a), which may point at disturbed
hepatocyte integrity (Keil, 1990). The alterations in serum
lipids and lipoprotein levels caused by coffee diterpenes
may also be due to effects on liver cell metabolism.
Apolipoprotein(a) is synthesised in the liver (Kraft et al,
1989), and circulating levels of Lp(a) are largely deter-
mined by the rate of production (Rader et al, 1993). Indeed
patients with biliary cirrhosis (Feely et al, 1992; Gregory et
al, 1994; van Wesch, 1994) or other liver diseases (Gregory
et al, 1994) have higher levels of lipids and liver amino-
transferases, but had reduced plasma (Lp(a) levels. It is thus
possible that the reduction of Lp(a) by coffee diterpenes is
also due to their effect on liver cell metabolism. Cross-
sectional studies showed that chronic consumers of boiled
(Weusten-van der Wouw et al, 1994) or espresso coffee
(Casiglia et al, 1993) had no elevated levels of alanine
amino transferase. However, it remains speculative whether
a transient effect on liver cell integrity may also result in an
adaptation of Lp(a) metabolism in the human body.
Conclusions
Coffee diterpenes, which are present in unfiltered coffee
brews, are among the few dietary constituents that mod-
ulate Lp(a) levels. An advise to switch from filtered to
unfiltered coffee is not warranted, as cafestol and kahweol
exert a range of other, negative health effects. The present
findings also indicate that caution is needed in extrapolating
results from short-term controlled trials to the chronic
situation.
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